EYLEA® 8mg DME

DME

EYLEA® 8mg (114.3 mg/ml) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).

For those who want flexibility to optimize patient’s treatment intervals to Q16 and beyond

Save sight whilst minimizing treatment burden

Save sight whilst minimising treatment burden
,

Flexibility to extend treatment intervals as far as Q20

Flexibility to extend treatment intervals across your clinic as far as Q20

Suppress VEGF with a safety profile comparable to EYLEA 2mg

Suppress VEGF with a safety profile comparable to EYLEA 2mg
,
,

PHOTON

Eylea® 8mg: The opportunity to extend treatment intervals with confidence

Primary endpoint: mean change in BCVA from baseline to Week 48

With EYLEA® 8mg, patients achieved lasting BCVA gains from baseline with as few as 5 injections in Year 1 (Includes 3 initial monthly doses.)

  • EYLEA® 8mg was non-inferior vs. EYLEA® 2mg

Week 48

Flexibility to extend treatment intervals for eligible DME patients

In PHOTON, ~9 out of 10 patients maintained 16-week treatment intervals from baseline through Week 48
*

Flexibility to extend treatment intervals for eligible DME patients

*Patients completing Week 48: 2Q8 n=157; 8Q12 n=300; 8Q16 n=156.

Week 96

Flexibility to extend treatment intervals for eligible patients across your DME clinic

In PHOTON, ~9 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 96
*

Flexibility to extend treatment intervals for eligible patients across your DME clinic

*Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.

Flexibility to extend treatment intervals beyond expectations

The first and only anti-VEGF for DME that allows for extension to treatment intervals of Q20 after reaching Q16
*

Flexibility to extend treatment intervals beyond expectations

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology. 
†Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.

Discover more about how you can meet the needs of your eligible nAMD patients with EYLEA® 8mg
arrow_forward

    2Q8, 2mg every 8 weeks. 8Q12, 8mg every 12 weeks. 8Q16, 8mg every 16 weeks. BCVA, best-corrected visual acuity. BMI, body mass index. CI, confidence interval. CRT, central retinal thickness. DME, diabetic macular edema. DRM, dosing regimen modification. DRSS, diabetic retinopathy severity study. ETDRS, Early Treatment of Diabetic Retinopathy Study. FAS, full analysis set. ICE, intercurrent event. LS, least squares. MMRM, mixed model for repeated measurements. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks. Q20, every 20 weeks. Q24, every 24 weeks. SAF, safety analysis set. SD, standard deviation. SmPC, Summary of Product Characteristics. T&E, treat and extend. VEGF, vascular endothelial growth factor.

PP-EYL_8mg-IL-0017-1

    • 1
      EYLEA® 8mg SmPC as approved by the Israeli MoH.
    • 2
      David M Brown
      et al
      . Intravitreal aflibercept 8mg in diabetic macular edema (PHOTON): 48-week results from a randomised, doublemasked, non-inferiority, phase 2/3 trial.The LANCET. Vol 403 March 23, 2024;1153-1163.
    • 3
      Wykoff CC. Aflibercept 8mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
    • 4
      Brown DM. Intravitreal aflibercept injection 8mg for DME: 48-week results from the Phase 2/3 PHOTON trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
    • 5
      ClinicalTrials.gov. NCT04429503. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04429503. Accessed: January 2024.